Liposomal daunorubicin

WikiDoc Resources for Liposomal daunorubicin
Articles
Most recent articles on Liposomal daunorubicin Most cited articles on Liposomal daunorubicin Review articles on Liposomal daunorubicin Articles on Liposomal daunorubicin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Liposomal daunorubicin Images of Liposomal daunorubicin Photos of Liposomal daunorubicin Podcasts & MP3s on Liposomal daunorubicin Videos on Liposomal daunorubicin
Evidence Based Medicine
Cochrane Collaboration on Liposomal daunorubicin Bandolier on Liposomal daunorubicin TRIP on Liposomal daunorubicin
Clinical Trials
Ongoing Trials on Liposomal daunorubicin at Clinical Trials.gov Trial results on Liposomal daunorubicin Clinical Trials on Liposomal daunorubicin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Liposomal daunorubicin NICE Guidance on Liposomal daunorubicin NHS PRODIGY Guidance FDA on Liposomal daunorubicin CDC on Liposomal daunorubicin
Books
Books on Liposomal daunorubicin
News
Liposomal daunorubicin in the news Be alerted to news on Liposomal daunorubicin News trends on Liposomal daunorubicin
Commentary
Blogs on Liposomal daunorubicin
Definitions
Definitions of Liposomal daunorubicin
Patient Resources / Community
Patient resources on Liposomal daunorubicin Discussion groups on Liposomal daunorubicin Patient Handouts on Liposomal daunorubicin Directions to Hospitals Treating Liposomal daunorubicin Risk calculators and risk factors for Liposomal daunorubicin
Healthcare Provider Resources
Symptoms of Liposomal daunorubicin Causes & Risk Factors for Liposomal daunorubicin Diagnostic studies for Liposomal daunorubicin Treatment of Liposomal daunorubicin
Continuing Medical Education (CME)
CME Programs on Liposomal daunorubicin
International
Liposomal daunorubicin en Espanol Liposomal daunorubicin en Francais
Business
Liposomal daunorubicin in the Marketplace Patents on Liposomal daunorubicin
Experimental / Informatics
List of terms related to Liposomal daunorubicin

Overview

Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS-related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.

Trade name: DaunoXome®

External links

• Cancerbackup Liposomal daunorubicin (DaunoXome®)
• Women&Cancer Magazine Liposomal daunorubicin
• Johns Hopkins AIDS Service - New from the Food and Drug Administration (FDA)